<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196260</url>
  </required_header>
  <id_info>
    <org_study_id>Dake Chu-200401</org_study_id>
    <secondary_id>StateKeyLab</secondary_id>
    <nct_id>NCT01196260</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III</brief_title>
  <official_title>Clinical Trial on Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III Among Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State Key Laboratory of Cancer Biology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Union Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beihua University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>State Key Laboratory of Cancer Biology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine a new combination of drugs: Capecitabine and Oxaliplatin for the&#xD;
      treatment of Stage II and III colorectal cancer. Capecitabine and Oxaliplatin are approved by&#xD;
      the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of drugs&#xD;
      is experimental (not approved by the FDA as standard treatment), but is a widely used&#xD;
      treatment option and preliminary studies have shown that treatment with the combination has a&#xD;
      positive effect on metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine a new combination of drugs: Capecitabine and Oxaliplatinfor for the&#xD;
      treatment of Stage II and III colorectal cancer. Capecitabine and Oxaliplatin are approved by&#xD;
      the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of drugs&#xD;
      is experimental (not approved by the FDA as standard treatment), but is a widely used&#xD;
      treatment option and preliminary studies have shown that treatment with the combination has a&#xD;
      positive effect on metastatic colorectal cancer. In the present trial, we will study the&#xD;
      combination of these two drugs in patients with colorectal cancer among Chinese population&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2004</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the objective response rate of patients with metastatic colorectal cancer received the combination of drugs</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the relapse of patients with metastatic colorectal cancer received the combination of drugs</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine prognosis of patients with metastatic colorectal cancer received the combination of drugs</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the time to progression of metastatic colorectal cancer after treatment</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>5-fluorouracil plus oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be randomized assigned to receive 5-fluorouracil plus oxaliplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine and Oxaliplatin</intervention_name>
    <description>Capecitabine and Oxaliplatin will be under the NSCLC guideline</description>
    <arm_group_label>5-fluorouracil plus oxaliplatin</arm_group_label>
    <other_name>1220099</other_name>
    <other_name>CDK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have a histologically proven TNM stage II or III adenocarcinoma of colon&#xD;
             or rectum.&#xD;
&#xD;
          -  Patient must received curative surgical with cancer free margin.&#xD;
&#xD;
          -  Patients must have a performance status of 0,1, or 2.&#xD;
&#xD;
          -  Patients must have an absolute neutrophil count of greater than or equal to 1500/ml,&#xD;
             platelet count greater than or equal to 100,000/ml, and total serum bilirubin equal or&#xD;
             less than the institution's upper limit or normal range.&#xD;
&#xD;
          -  Patients must have fully recovered from any effects of surgery.&#xD;
&#xD;
          -  Patients must provide a signed consent to participate in the study.&#xD;
&#xD;
        Age:&#xD;
&#xD;
        •18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
        •WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
        •Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
        •Creatinine clearance greater than 30 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
        More than 12 months since prior and no active clinically significant cardiovascular&#xD;
        disease, including any of the following:&#xD;
&#xD;
          -  Cerebrovascular accident&#xD;
&#xD;
          -  Myocardial infarction&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
          -  Serious cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  Uncontrolled hypertension (i.e., blood pressure &gt; 150/100 mm Hg)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active peptic ulcer or gastrointestinal bleeding within the past year&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No other malignancy within the past 10 years except adequately treated carcinoma in&#xD;
             situ of the cervix or basal cell or squamous cell skin cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a proven history of peptic ulcer disease or gastroesophageal reflux.&#xD;
&#xD;
          -  Patients who have experienced asthma, urticaria, or allergic-type reactions after&#xD;
             taking aspirin or other non-steroidal anti-inflammatory drugs.&#xD;
&#xD;
          -  Patients who have received prior chemotherapy for colorectal cancer except for&#xD;
             patients relapsing more than 6 months after completion of adjuvant chemotherapy.&#xD;
&#xD;
          -  History of other malignancy, except for cancers that have been treated with a curative&#xD;
             intent and patient is without evidence of active disease.&#xD;
&#xD;
          -  Unresolved bacterial infection requiring treatment with antibiotics.&#xD;
&#xD;
          -  Pregnant or lactating women may not participate in the study. Women/men of&#xD;
             reproductive age group may not participate unless they have agreed to use an effective&#xD;
             method of contraception.&#xD;
&#xD;
          -  Patients who have allergy to any of the study drugs.&#xD;
&#xD;
          -  Patients known to have HIV-1 virus infection because of the undetermined effect of&#xD;
             this chemotherapy regimen in patients with HIV-1 and the potential for serious&#xD;
             interaction with anti-HIV medications.&#xD;
&#xD;
          -  Gilbert's disease.&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract. Inability to swallow&#xD;
             tablets or those who have malabsorption syndrome.&#xD;
&#xD;
          -  Other serious concurrent infection&#xD;
&#xD;
          -  Clinically significant cardiac disease not well controlled with medication (e.g.&#xD;
             congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias)&#xD;
             or myocardial infarction within the last 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dake Chu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Air Force Military Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dake Chu, M.D.</last_name>
    <phone>86-29-84774516</phone>
    <email>chudake@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>State Key Laboratory of Cancer Biology</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dake Chu, M.D.</last_name>
      <phone>86-29-84774516</phone>
      <email>chudake@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.fmmu.edu.cn</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <last_update_submitted>February 18, 2018</last_update_submitted>
  <last_update_submitted_qc>February 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State Key Laboratory of Cancer Biology</investigator_affiliation>
    <investigator_full_name>Dake Chu</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>efficiency</keyword>
  <keyword>capecitabine</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

